loader
Please Wait
Applying Filters...

Annual Sales of PIPERACILLIN; TAZOBACTAM reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Menu
$ API Ref.Price (USD/KG) : 122Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1Zosyn

02 4Zosyn/Tazocin

PharmaCompass

01

Brand Name : Zosyn/Tazocin

Piperacillin

arrow
Discovery on Target
Not Confirmed

Brand Name : Zosyn/Tazocin

arrow
Discovery on Target
Not Confirmed

Piperacillin

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2019 Revenue in Millions : 200

2018 Revenue in Millions : 230

Growth (%) : -13

blank

02

Brand Name : Zosyn

Piperacillin and Tazobactam

arrow
Discovery on Target
Not Confirmed

Brand Name : Zosyn

arrow
Discovery on Target
Not Confirmed

Piperacillin and Tazobactam

Main Therapeutic Indication : Infectious Diseases (HIV, Hepatitis...

Currency : USD

2014 Revenue in Millions : -23.30%

2013 Revenue in Millions :

Growth (%) :

blank

03

Brand Name : Zosyn/Tazocin

Piperacillin And Tazobactam

arrow
Discovery on Target
Not Confirmed

Brand Name : Zosyn/Tazocin

arrow
Discovery on Target
Not Confirmed

Piperacillin And Tazobactam

Main Therapeutic Indication : Anti-Bacterial

Currency : USD

2016 Revenue in Millions : 81

2015 Revenue in Millions : 117

Growth (%) : -31

blank

04

Brand Name : Zosyn/Tazocin

Piperacillin and Tazobactam

arrow
Discovery on Target
Not Confirmed

Brand Name : Zosyn/Tazocin

arrow
Discovery on Target
Not Confirmed

Piperacillin and Tazobactam

Main Therapeutic Indication : Anti-bacterial

Currency : USD

2017 Revenue in Millions : 60

2016 Revenue in Millions : 84

Growth (%) : -28

blank

05

Brand Name : Zosyn/Tazocin

Piperacillin and Tazobactam

arrow
Discovery on Target
Not Confirmed

Brand Name : Zosyn/Tazocin

arrow
Discovery on Target
Not Confirmed

Piperacillin and Tazobactam

Main Therapeutic Indication : Anti-bacterial

Currency : USD

2018 Revenue in Millions : 0

2017 Revenue in Millions : 57

Growth (%) : -100%

blank